 Fingolimod Hydrochloride
"Fingolimod Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068876
|
| MeSH Number(s) |
D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350
|
| Concept/Terms |
Fingolimod Hydrochloride- Fingolimod Hydrochloride
- Hydrochloride, Fingolimod
- 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Fingolimod Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Fingolimod Hydrochloride".
This graph shows the total number of publications written about "Fingolimod Hydrochloride" by people in this website by year, and whether "Fingolimod Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2017 | 1 | 3 | 4 | | 2018 | 4 | 0 | 4 | | 2019 | 2 | 0 | 2 | | 2020 | 3 | 0 | 3 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Fingolimod Hydrochloride" by people in Profiles.
-
Jakobs M, Trautmann L, Hadamitzky M, Bihorac J, Jacquet L, Christians U, Schniedewind B, L?ckemann L, Schedlowski M. Behavioral Analyses in Dark Agouti Rats Following Repeated Systemic Treatment With Fingolimod (FTY720). Brain Behav. 2024 Nov; 14(11):e70146.
-
Fonseca Balladares DC, Kassa B, Mickael C, Kumar R, Nolan K, Menezes TCF, Lee MH, Lau-Xiao AM, Molofsky AB, Wells E, Graham BB. Intrapulmonary T Cells Are Sufficient for Schistosoma-Induced Pulmonary Hypertension. Int J Mol Sci. 2024 Aug 24; 25(17).
-
Danielson SM, Lefferts AR, Norman E, Regner EH, Schulz HM, Sansone-Poe D, Orlicky DJ, Kuhn KA. Myeloid Cells and Sphingosine-1-Phosphate Are Required for TCRa? Intraepithelial Lymphocyte Recruitment to the Colon Epithelium. J Immunol. 2024 Jun 01; 212(11):1843-1854.
-
Jakobs M, H?rbelt-Gr?nheidt T, Hadamitzky M, Bihorac J, Salem Y, Leisengang S, Christians U, Schniedewind B, Schedlowski M, L?ckemann L. The Effects of Fingolimod (FTY720) on Leukocyte Subset Circulation cannot be Behaviourally Conditioned in Rats. J Neuroimmune Pharmacol. 2024 May 11; 19(1):18.
-
Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, Chitnis T, Gorman M, Benson LA, Rodriguez M, Tillema JM, Krupp L, Schreiner T, Mar S, Rensel M, Rose J, Liu C, Guye S, Manlius C, Waubant E. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647.
-
Malani Shukla N, Casper TC, Ness J, Wheeler Y, Chitnis T, Lotze T, Gorman M, Benson L, Weinstock-Guttmann B, Aaen G, Rodriguez M, Tillema JM, Krupp L, Schreiner T, Mar S, Goyal M, Rensel M, Abrams A, Rose J, Waltz M, Liu T, Manlius C, Waubant E. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatr Neurol. 2023 08; 145:125-131.
-
Goel K, Schweitzer KS, Serban KA, Bittman R, Petrache I. Pharmacological sphingosine-1 phosphate receptor 1 targeting in cigarette smoke-induced emphysema in mice. Am J Physiol Lung Cell Mol Physiol. 2022 06 01; 322(6):L794-L803.
-
Zehra Okus F, Busra Azizoglu Z, Canatan H, Eken A. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo. Int Immunopharmacol. 2022 Jun; 107:108665.
-
Kowarik MC, Astling D, Lepennetier G, Ritchie A, Hemmer B, Owens GP, Bennett JL. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics. 2021 01; 18(1):364-377.
-
Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|